Background: Electrophysiologic effects of a beta-blocking agent, tilisolol, were studied with isolated guinea pig ventricular myocytes using the whole cell patch clamp technique.
Methods and Results:. Tilisolol at 10 μM or higher concentrations prolonged action poten tial duration (APD) at 90% repolarization (APD90) and at 100 μM or higher concentrations shortened APD at 20% repolarization (APD20) without changes in resting membrane poten tial. At 10 μM concentration tilisolol prolonged APD90 from 236.6 ± 55.3 ms in the control to 253.4 ± 52.4 ms (n = 16; P < .0 L), while APD20 was unaffected. At 100 μM tilisolol, APD20 was shortened from 143.6 ± 15.7 ms in the control to 133.7 ± 22.6 ms (n = 8; P < .05). Under voltage clamp, tilisolol decreased the delayed rectifier K+ current (IK), while the drug little affected the inward rectified K+ current (IKI). Applications of 10 μM and 100 μM tilisolol reduced the maximal conductance of IK by 35.7 ± 3.5% and 47.4 ± 3.5% of the control, respectively, without changes in voltage dependence (n = 10). Tilisolol at 100 μM decreased the L-type Ca2+, current (I Ca.L) by 22.0 ± 9.8% (n = 6) of the control, and the inactivation curve was shifted to a hyperpolarizing direction.
Conclusions: Tilisolol has a direct membrane action to depress IK and ICa.L, in addition to its beta-receptor blocking action.
Vanzwieten PAPharmacology of antihypertensive agents with multiple actions. Eur J Clin Pharmacol38:S77, 1990
2.
TheCardiac Arrhythmia Suppression Trial (CAST) Investigators: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med321:406, 1989
3.
Singh BN, Vaughan Williams EMA third class of antiarrhythmic action: Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474. Br J Pharmacol39:675, 1970
4.
Mason JW for the ESVEM Investigators: A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias . N Engl J Med329:452, 1993
5.
Sugai T., Kojima K., Iwakami N., Suzuki Y.Vasorelaxant and hypotensive effects of tilisolol hydrochloride (N-696) in isolated rat thoracic aorta and pithed rats. Jpn J Pharmacol57:367, 1991
6.
Nakagawa Y., Sugai T., Chin WP, Shibuya T., Hashimoto K., Imai S.Pharmacological profile of a new beta-adrenoceptor blocker, 4-[3-(tert-butylamino)-2-hydroxypropoxy]-N-methylisocarbostyril hydrochloride (N-696). Arzneim Forsch34:194, 1984
7.
Ishii M., Komori S., Satoh H., Ohta T., Motomura S., Hashimoto K.Effects of N-696, a new beta-blocking agent, on canine experimental arrhythmias . Folia Pharmacol Japon84:259, 1984
8.
Tsukiyama H. , Otsuka K., Takasaki I., Horii M.Hemodynamic effects of dilevalol and N-696, new beta-blocking agents with vasodilating properties, and doxazosin and urapidil new alpha-blocking agents, in essential hypertension. J Cardiovasc Pharmacol11 (Suppl 2):S32, 1988
9.
Imaizumi T., Takeshita A., Nakamura N., Hirooka Y., Suzuki S., Yoshida M., Nakamura M.Vasodilating effect of the new beta-blocker tilisolol hydrochloride in humans . Arzneim Forsch38:1342, 1988
10.
Hashimoto K. , Satoh H., Shibuya T., Imai S.Canine-effective plasma concentrations of antiarrhythmic drugs on the two-stage coronary ligation arrhythmia. J Pharmacol Exp Ther223:801. 1982
11.
Shibuya T., Hashimoto K., Imai S.Effective plasma concentrations of antiarrhythmic drug agonists sustained halothaneadrenaline arrhythmia in dogs. J Cardiovasc Pharmacol5:538, 1983
12.
Hirano Y., Hiraoka M.Barium-induced automatic activity in isolated ventricular myocytes from guinea-pig hearts. J Physiol (Lond) 395:455, 1988
13.
Isenberg G. , Klockner U.Calcium tolerant ventricular myocytes prepared by preincubation in a "KB medium". Pflugers Arch395:6, 1982
14.
Noma A.ATP-regulated K+ channels in cardiac muscle. Nature305:147, 1983
15.
Singh BN, Deedwania P., Nademanee K., Ward A., Sorkin EMSotalol: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs34:311, 1987
16.
Singh BN, Antonaccio MJSotalol and d-sotalol in the control of cardiac arrhythmias. In Singh BN, Dzau V, Vanhoutte PM, Woosley RL (eds). Cardiovascular Pharmacology and Therapeutics. Churchill Livingstone, New York, pp. 727-746, 1994
17.
Lynch JJ, Wilber DJ, Montgomery DG, Hsieh TM, Patterson E., Lucchesi BRAntiarrhythmic and antifibrillatory actions of the levo- and dextrorotatory isomers of sotalol. J Cardiovasc Pharmacol6:1132, 1984
18.
Carmeliet E.Electrophysiologic and voltage clamp analysis of the effects of sotalol on isolated cardiac muscle and Purkinje fibers. J Pharmacol Exp Ther232:817, 1985
19.
Komeichi K. , Tohse N., Nakaya H., Shimizu M., Zhu MY; Kanno M.Effects of N-acetylprocainamide and sotalol on ion currents in isolated guinea-pig ventricular myocytes. Eur J Pharmacol187:313, 1990
20.
Sanguinetti MC, Jurkiewicz NKTwo components of cardiac delayed rectifier K+ current. J Gen Physiol96:195, 1990
21.
Kubota N., Hagiwara K., Sugai T., Nagase M., Suzuki Y., Kobayashi A.Pharmacology of a beta-adrenergic blocking drug, (I)-4-(3-tert-butylamino-2-hydroxypropoxy)-2-methyl-1(2H)-isoquinolinone hydrochloride (N-696). Clinical Report22:1705, 1988
22.
Nelson MT, Patlak JB, Worley JF, Standen NBCalcium channels, potassium channels, and voltage dependence of artrial smooth muscle tone. Am J Physiol259:C3, 1990
23.
Beta-blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction: I. Mortality results. JAMA247:1707, 1982
